NeuroBo Pharmaceuticals Inc. (NRBO) on Monday reported a net loss of $4.08 per share for the year ended Dec. 31, compared with a loss of $3.65 per share a...
NeuroBo Pharmaceuticals (NRBO) said Richard Kang has been appointed president and chief executive officer retrospectively from Jan. 1. Shares jumped by...
Gemphire Therapeutics (GEMP) said that its pending merger with NeuroBo Pharmaceuticals is expected to close after market hours Monday. Gemphire's...
Here's how the stocks on Tuesday's After Hours Watch List performed during today's regular session AFTER HOURS REGULAR SESSION GEMP +4.91% ...
| Address | 200 Berkeley Street Boston, Massachusetts 02116 |
| Phone | +1.617.313.7331 |
| Number of Employees | 9 |
| Recent SEC Filing | 04/01/2020 S-8 |
| President, Chief Executive & Financial Officer | Jeong Gu Kang |
| Chief Medical Officer | Mark Versavel |
| Vice President-Clinical Operations | Nicola Shannon |
| Price Open | $14.01 |
| Previous Close | $14.27 |
| 52 Week Range | $5.95 - 36.22 |
| Market Capitalization | $247.7 M |
| Shares Outstanding | 15.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 05/14/2020 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.90 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -419.70% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
